Search PubMed⌕ Search

Biomedical subjects

R H Yonemoto

Publications and source records attributed to R H Yonemoto.

At least 19 recordsLinked to original sources

Acral lentiginous melanoma. A clinicopathologic study of 36 patients.

Acral lentiginous melanoma (ALM) is a distinct variant of malignant melanoma with a predilection for the soles, palms, and nail beds. This melanoma has characteristic histologic features, and its biologic behavior is similar to that of nodular melanoma. It occurs predominantly in the sixth, seventh, and eighth decades of life, with a peak incidence in the seventh decade for males and in the sixth decade for females. Diagnosis of ALM during the radial growth phase is often difficult, and it may not be recognized initially, but treatment in this phase offers an excellent prognosis. There is a high incidence of regressive changes and desmoplasia in ALM; these changes, together with the anatomic peculiarities of nail beds, palms, and soles as compared with other skin areas, make it difficult to determine the Clark's level and to measure the depth of invasion. Wide local excision with lymph node dissection is recommended for subungual melanomas measuring more than 1.00 mm and for lesions showing severe regression. Volar melanomas less than 1.00 mm deep and those in the radial growth phase with minimal invasion require only wide local excision. Amputation of digits and lymph node dissection are recommended for subungual melanomas, if the melanomas exhibit the vertical growth phase. If there is only radial growth without regressive changes, wide local excision is adequate. Patients with metastasis to lymph nodes at the time of diagnosis usually have shorter survival times than do those without lymph node involvement (P = 0.027).

Adolescent↗

Biologic behavior of thin malignant melanomas with regressive changes.

Thin cutaneous malignant melanomas are defined as lesions measuring less than 0.76 mm in maximal thickness. Eight of the 36 thin lesions that we studied metastasized within two to 120 months. Of the 11 lesions with regressive features, five (45.5%) metastasized. Of 25 lesions without regression, only three (12%) metastasized. Thin melanomas with regressive changes need to be reported as a separate category because of their propensity to metastasize. Conventional prognostic guidelines for treatment of thin melanomas are not applicable to this type of lesion. Clinicians need to be cognizant that regressive changes are serious warning signals when they occur in thin melanomas.

Adult↗

Mouse monoclonal antibody to a melanoma-carcinoma-associated antigen synthesized by a human melanoma cell line propagated in serum-free medium.

A monoclonal antibody, F11, was produced against a tumor-associated antigen from the spent medium of the M14 human malignant melanoma cell line which was grown continuously in serum-free medium. Ouchterlony double-diffusion study revealed that the F11 monoclonal antibody is an immunoglobulin G1. The F11 monoclonal antibody reacted positively with seven of eight (88%) melanoma, five of five (100%) carcinoma, zero to five normal, and zero of two lymphoblastoid cell lines by indirect immunofluorescence test. Also, by indirect immunofluorescence test, F11 monoclonal antibody reacted with cryostat sections from four of five (80%) melanomas, six of seven (86%) carcinomas, zero of one benign nevus, and zero of two benign breast diseases. By the indirect avidin:biotin:peroxidase complex immunoperoxidase method, the F11 monoclonal antibody reacted positively with cryostat sections from five of five (100%) melanomas, five of five (100%) breast cancers, two of two (100%) colon cancers, zero of one benign nevus, and zero of one Hodgkin's disease spleen. Thus, the tumor-associated antigen that the F11 monoclonal antibody recognizes appears to be expressed by melanomas and carcinomas, hence the designation melanoma-carcinoma-associated antigen. Microscopic observations disclosed that the melanoma-carcinoma-associated antigen is present in the cytoplasm, on the membrane of melanoma and carcinoma cells, and in the lumen of glandular structures of breast and colon carcinomas. The molecular weight of the melanoma-carcinoma-associated antigen in spent medium from the M14 CEM cell line is 100,000 as determined by sodium dodecyl sulfate:polyacrylamide gel electrophoretic analysis of indirect immunoprecipitates obtained with the F11 monoclonal antibody.

Animals↗

Comparison of serum blocking factors on leucocyte adherence inhibition and PHA lymphocyte blastogenesis in breast cancer patients.

Specific and nonspecific serum blocking factors (SBF) in sera from 48 breast cancer patients were examined to evaluate the correlation of SBF to the tumor burden. Specific SBF in leucocyte adherence inhibition (LAI) assay was demonstrated in 15 of 21 patients with a recurrence, in five of 11 with local or regional involvement and in 3 of 16 with no evidence of the disease (NED). The difference between patients with recurrence and with NED was significant (P less than 0.005). SBF in LAI and lymphocyte blastogenesis correlated in 29 of 48 (60%) patients (both positive 9 of 48, both negative 20 of 48). However, SBF in LAI was demonstrated in 14 of 48 (29%) patients whose sera showed no SBF in lymphocyte blastogenesis. These results indicate that SBF in LAI and lymphocyte blastogenesis are either induced or derived from breast cancer tissue. SBF in LAI correlates closely with the tumor burden, more so than do SBF in lymphocyte blastogenesis. The blocking assays have a potential use for prognostication and a guide for clinical therapy.

Antigen-Antibody Complex↗

Breast cancer in Japan and United States: epidemiology, hormone receptors, pathology, and survival.

Breast cancer is the most common cancer among American women, whereas in Japan it ranks third behind gastric and uterine cancers. In spite of the relatively low incidence of breast cancer in Japan, a sharp increase in the frequency has been noted since 1966, which is decidedly related to change in dietary patterns in Japanese women. An increase of over 250% in dietary intake of fat has been noted during the past 15 years. Cancer is detected at an earlier stage in Japan as compared with the United States, and consequently the end result is significantly better. But the improved results could not be totally explained on the basis of early detection, since stage-for-stage the Japanese series appears to be consistently better than the US series by 10% in their ten-year survival rates.

Adult↗

Automation of the leukocyte adherence inhibition assay. Counting live mononuclear cells with an automated light microscope system.

Adaptation of an automated light microscope system to the leukocyte adherence inhibition assay provides a rapid automated assay of cell mediated immunity. Comparison between the numbers of live mononuclear cells counted by eye and by machine yields no statistical differences in the per cent adherence or in the standard errors when performing either 10 or 20 replicate counts per antigen-cell mixture. Using the cell counter in a semi-automated mode, the counting is performed 10 times as fast in comparison to the manual method. A semi-automated system is described. The procedure requires from 4-6 X 10(5) mononuclear cells and from 2-3 micrograms crude KCl extract using a standard hemocytometer. The value of the technique lies in its availability as a rapid assay for both research applications and immunologic monitoring in the clinical laboratory.

Humans↗

Effect of serum factors and cell washings on leukocyte adherence inhibition in breast cancer patients.

A total of 81 individuals, including 41 breast cancer patients, 20 patients with other types of malignant tumors, and 20 normal volunteers, were studied in order to evaluate whether leucocyte reactivity directed to soluble tumor-associated antigens could be increased by extensive cell washings and could be blocked by preincubation with autologous serum. When 41 leucocyte samples were pretreated with autologous serum, washed 3 or 6 times, mean percentage of leucocyte adherence inhibition difference between control extract and breast cancer extract were -2.4 +/- 2.0, 5.8 +/- 1.3, and 10.0 +/- 1.2, respectively. The results of cells preincubated with serum were significantly different from those of cells washed 3 times and 6 times (both P less than 0.001 by Student's t-test). The results of cells washed 3 times were significantly different from those of cells washed 6 times (P less than 0.05 by Student's t-test). Serum blocking factors correlated with tumor burden and clinical stage. However, leucocyte reactivity against breast cancer extract did not correlate with tumor burden or clinical stage in breast cancer patients.

Adult↗

Analysis of sera from patients with breast cancer for blocking and induction of leukocyte adherence inhibition.

The correlation of serum capacity for blocking and arming with effector cell reactivity has been examined in patients with breast cancer by using the leukocyte adherence inhibition (LAI) assay. It was found that sera from breast cancer patients possessed the ability to make nonimmune mononuclear cells specifically reactive (i.e., armed) to the breast cancer extract and to specifically block the reactivity of mononuclear cells from breast cancer patients with the cancer extract. Sera from patients with breast cancer whose mononuclear cells were nonreactive to the corresponding tumor extract (6/8) showed higher blocking than sera from patients whose cells showed reactivity to the corresponding tumor extract (3/13). Similarly, sera from patients with positive LAI response (6/13) induced arming of normal mononuclear cells more often than sera from patients with negative LAI (2/8). There also appeared to be an inverse correlation between the capacities of serum from breast cancer patients to exhibit blocking and arming. That is, serum arming activity was found only in sera which showed no blocking, and serum blocking activity was detected only in sera without arming, activity, except for one sample. The possibility is discussed that immune complexes play a key role in both serum activities, and that their biphasic character might be dependent on the ratio of antigen of antibody.

Antigen-Antibody Complex↗

Is SP1 (pregnancy specific beta 1 glycoprotein) elevated in cancer patients?

Pregnancy-specific beta 1-glycoprotein, SP1, was measured in serum by competitive double antibody radioimmunoassay. Very low levels of SP1 or SP1-like activity were found in only 2 out of 85 sera from patients with cancer of the digestive tract, breast cancer, melanoma, and sarcoma, in 2 out of 11 sera from patients with infectious diseases, and in none out of 15 sera from non-pregnant healthy individuals. SP1 thus does not seem to be ectopically produced in vivo by the types of cancer studied, but is probably highly specific for the normal and malignant trophoblast.

Breast Neoplasms↗

Immune responses in the treatment of advanced carcinoma of the breast. Effects of adrenalectomy.

We set out to answer the question, "Is the effect of adrenalectomy associated with or mediated through the immune response?" Eleven patients were studied preoperatively and postoperatively by in vitro immunologic tests. The assay system used included absolute T cell counts, phytohemagglutinin (PHA) blastogenesis, leukocyte adherence inhibition (LAI) after contact with 3M potassium chloride breast antigens, and blocking as measured in the blastogenesis and LAI assays. Good correlation was found between favorable clinical response to adrenalectomy and a rise in the number of absolute T cells, an increase in LAI positivity, and a decrease in blocking as measured by LAI blocking assay, but no correlation was seen in PHA blastogenesis assays. The association of clinical objective responses and improved immune responses is of significance.

Adrenalectomy↗

Leukocyte adherence inhibition by soluble tumor antigens in breast cancer patients.

The authors modified and refined the Leukocyte Adherence Inhibition Assay (LAI) first described by Halliday, et al. in 1972 by standardizing the protein concentration of tumor-associated antigens (TAA) and by utilizing paired normal tissue extracts as controls to eliminate interference of HL-A histocompatibility antigens and organ-associated antigens. When dose response studies were performed, a progressively larger percentage of patients reacted to the LAI test with increasing concentration of tumor extracts, but the optimal concentration was found to be 200 mug/ml, where 42 out of 66 (63%) leukocytes from 54 breast cancer patients reacted to the breast cancer extracts. At this dose range, only three out of 39 (7%) normal donors and four out of 30 (13%) patients with other types of cancer were positive. When breast cancer patients were tested against TAA of colon cancer and malignant melanoma, one of 24 (4%) and two of 24 (8%), respectively, were positive. Although a higher response rate (72%) was noted in Stage II disease, this was not statistically different from Stage I and Stage III disease. Likewise, no difference was noted in LAI at varying phases following the mastectomy.

Adult↗

Randomized sequential hormonal therapy vs adrenalectomy for metastatic breast carcinoma.

One hundred sixty-one postmenopausal and 65 premenopausal women, a total of 226 patients with metastatic breast carcinoma, were included in this randomized study to evaluate the merits of adrenalectomy as the primary mode of therapy as compared to the customary sequential hormonal manipulation. The 145 evaluable postmenopausal patients were randomized as follows: (1) primary additive hormone therapy first followed by adrenalectomy and (2) primary adrenalectomy followed by chemotherapy and/or additive hormone therapy. When 76 patients in group 1 were compared with 70 patients in group 2 regarding their survival time, there was no essential difference, but the response rate was 20% vs 38.6%, a significant difference. The 55 evaluable premenopausal women were randomized into two groups: (1) oophorectomy followed by adrenalectomy; (2) adrenalectomy-oophorectomy as primary mode of therapy. The response rate in group 1 was 17.4% as compared with 41.9% in group 2, but again there was no difference in the survival time among these two groups. When sequential hormonal manipulation was utilized, only one-third of these patients were subjected to adrenalectomy because of their rapidly deteriorating condition. Adrenalectomy performed as a secondary procedure showed a lower response rate but the total survival time was comparable with primary adrenalectomy patients.

Adrenalectomy↗

In vitro activity of the fatty acyl desaturases of human cancerous and noncancerous tissues.

The microsomal desaturase activity of human cancerous and noncancerous tissues was measured in vitro using 1-14C, -11, 14-eicosadienoic and 1-14C-oliec acids as substrates. Tissues used were a case of ovarian cancer, a urinary bladder cancer, a rectal cancer, and a non-specific colonic ulcer with appropriately normal tissues. When 11, 14-20:2 was used as substrate, radioactive tetraene and triene were produced. The tetraene was identified by radio gas chromatography as arachidonic acid (5, 8, 11, 14-20:4), and the triene had a retention time of 5, 11, 14-20:3. Thus, the possibility arises that a delta8 desaturase was involved. In the delta6 desaturase, with the urinary bladder cancerous tissue, the desaturase activity appeared to be decreased in comparison to neighboring tissue, whereas with the colonic cancer tissue, the desaturase appeared to be relatively increased, though the number of samples was inadequate for confidence.

Adult↗